Daniella Kranjac
Founding Partner @ Dynamk Capital
New York, United States
Daniella Kranjac is a Series A investor at Dynamk Capital in New York focused on Biotechnology and Medical. Daniella Kranjac is the Founding Partner of Dynamk Capital, LLC, founded in 2017 to support early and growth stage life science companies. Daniella has deep domain experience in life sciences as an entrepreneur, corporate executive, advisor, and investor. She began her career as a Co-Founder of Wave Biotech LLC where she drove the growth ofdisruptive technology, building the company and leading the group to a successful exit and acquisition by GE Healthcare in 2007. At GE, Daniella held several strategic, business development, M&A, and commercial leadership roles, creating a several hundred-million-dollar Enterprise Solutions business. She holds a bachelor’s degree in chemical engineering from the Stevens Institute of Technology, an Executive MBA from NYU Stern School of Business, and a Private Equity and VC Certification from the Harvard Business School Executive Program.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 78%
Last updated:
For AI agents: llms.txt
Industries Daniella Kranjac invests in
Stages Daniella Kranjac invests in
Countries Daniella Kranjac invests in
Investment Focus
Industry
- Biotechnology 6 (67%)
- Medical 2 (22%)
- Medical Device 2 (22%)
- Nanotechnology 2 (22%)
- Chemical 1 (11%)
Stage
- Series A 3 (33%)
- Series B 3 (33%)
- Seed 1 (11%)
- Funding Round 1 (11%)
Country
- United States 3 (33%)
- Canada 2 (22%)
- France 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AbbeLight
|
Abbelight offers innovative solutions in the field of super-resolution microscopy (nanoscopy) and membrane imaging for biological research. The company's single molecule localization microscopy is a combination of consumable, hardware and software techniques to achieve reliable state-of-the-art science, enabling companies conducting researchin the fields of biology, pharmacology and environment to implement super-resolved fluorescence microscopy approaches to observe biological samples with better resolution.Abbelight ambitions to make these cutting-edge techniques accessible to all laboratories by simplifying their use, without sacrificing the performance of instruments. To accomplish this, they accompany scientists from the preparation of the samples to the treatment of the results by proposing chemistry, computer science and optical instruments. | Series B / Jan 08, 2026 | |
Nomic
|
Nomic is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. They are building the nELISA, a next-generation protein profiling platform for measuring proteins at scale and at high throughput. They offer scientists protein profiling solutions and empower them to decide the scope and scaleof their experiments. | $42M / Series B / Sep 17, 2024 | |
Virica Biotech
|
Virica Biotech is a biotechnology company that addresses the unmet needs in production and development to positively change human health. Its Viral Sensitizer technology consists of a library of over one hundred small molecules that can safely overcome the natural immunological defenses in the human and animal body that suppress effective viralmedicines. | Series A / Oct 04, 2021 | |
Envisagenics
|
Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused bymutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered.Their breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. | $19.2M / Series A / Sep 29, 2021 | |
RoosterBio
|
RoosterBio is a biotechnology company, offers synthetic biology and regenerative medicine. The team at RoosterBio leads the field of new-thinkers in stem cell research and commercialization. The company is committed to simplifying, de-risking, and de-bottlenecking your lab, liberating you to do more high-impact research.It was founded in 2012 andheadquartered in Frederick, Maryland. | $6.5M / Series B / Sep 11, 2019 | |
|
Envisagenics
|
Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused bymutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered.Their breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. | $2.4M / Seed / Nov 28, 2017 | |
Flodesign Sonics
|
FloDesign Sonics is changing the separations and filtration markets through a novel acoustic technology. By leveraging breakthroughs in the use of 3D acoustic standing waves, FloDesign Sonics is able to capture, separate and purify without using physical membranes, chemicals, or centrifugation. Our proprietary technology has numerous applicationsin a variety of markets including life sciences, oil and gas, food and beverage and industrial processing. The first commercial application is in bioprocess separations where FloDesign Sonics is applying acoustic technology to the manufacturing of life saving bio-pharmaceuticals. For more information, contact info@fdsonics.com | ||
|
RoosterBio
|
RoosterBio is a biotechnology company, offers synthetic biology and regenerative medicine. The team at RoosterBio leads the field of new-thinkers in stem cell research and commercialization. The company is committed to simplifying, de-risking, and de-bottlenecking your lab, liberating you to do more high-impact research.It was founded in 2012 andheadquartered in Frederick, Maryland. | $15M / Series B | |
|
Flodesign Sonics
|
FloDesign Sonics is changing the separations and filtration markets through a novel acoustic technology. By leveraging breakthroughs in the use of 3D acoustic standing waves, FloDesign Sonics is able to capture, separate and purify without using physical membranes, chemicals, or centrifugation. Our proprietary technology has numerous applicationsin a variety of markets including life sciences, oil and gas, food and beverage and industrial processing. The first commercial application is in bioprocess separations where FloDesign Sonics is applying acoustic technology to the manufacturing of life saving bio-pharmaceuticals. For more information, contact info@fdsonics.com | Series A |
Co-Investors
About Dynamk Capital
Dynamk Capital invests in innovative tools and technologies that are critical for the discovery, development and production of life-saving therapies.We partner with life science visionaries whose market-defining ideas are shaping the future of how therapeutics are being developed, increasing access for patients, and reducing costs.
Dynamk Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Daniella Kranjac
Founding Partner
|
|||
Reinhard Vogt
Managing Director
|
|||
Gustavo Mahler
Venture Partner
|
|||
Sebastien Latapie
Principal
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Daniella Kranjac invest in?
Daniella Kranjac invests primarily in Biotechnology, Medical and Medical Device startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Daniella Kranjac last invest?
The most recent investment recorded for Daniella Kranjac closed in Jan 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
